Abstract：OBJECTIVE: To study the relationship of serum 25-hydroxyvitamin D [25-(OH)D3] level with obesity and inflammatory cytokines in children, and to provide a basis for clinical evaluation of the relationship between vitamin D nutritional status and obesity. METHODS: Seventy-eight children with obesity who visited the hospital between February and June 2012 were selected as subjects. According to baseline data, such as age and sex, 105 children who underwent physical examination in the same period were selected as controls. Fasting venous blood samples were taken to measure serum levels of 25-(OH)D3, interleukin-6 (IL-6), interleukin-8 (IL-8), interferon-γ (IFN-γ), and tumor necrosis factor α (TNF-α). RESULTS: Serum 25-(OH)D3 levels were significantly lower in the obesity group than in the control group (P0.05). CONCLUSIONS: Obese children have lower serum 25-(OH)D3 levels than normal children. Serum 25-(OH)D3 level is negatively correlated with BMI, but has little correlation with inflammatory cytokines levels.
FENG Ling,LI Jin-Rong,YANG Fan. Relationship of serum 25-hydroxyvitamin D with obesity and inflammatory cytokines in children[J]. CJCP, 2013, 15(10): 875-879.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030[J]. Diabetes Care, 2004, 27(5): 1047-1053.
[3]
Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages[J]. Cell Immunol, 2012, 280(1): 36-43.
Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions[J]. Diabetes Care, 2003, 26(3): 575-581.
[9]
Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations[J]. Pediatrics, 2008, 122(2): 398-417.
[10]
Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences[J]. Am J Clin Nutr, 2008, 87(4): 1080S-1086S.
[11]
Aloia JF. African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox[J]. Am J Clin Nutr, 2008, 88(2): 545S-550S.
[12]
Devaraj S, Jialal G, Cook T, Siegel D, Jialal I. Low vitamin D levels in Northern American adults with the metabolic syndrome [J]. Horm Metab Res, 2011, 43(1): 72-74.
[13]
de Paula FJ, Dick-de-Paula I, Bornstein S, Rostama B, Le P, Lotinun S, et al. VDR haploinsufficiency impacts body composition and skeletal acquisition in a gender-specific manner [J]. Calcif Tissue Int, 2011, 89(3): 179-191.
[14]
Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha, 25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action[J]. FASEB J, 2001, 15(14): 2751-2753.
[15]
DeLuca HF. Overview of general physiologic features and functions of vitamin D[J]. Am J Clin Nutr, 2004, 80(6 Suppl): 1689S-1696S.
[16]
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity[J]. Am J Clin Nutr, 2000, 72(3): 690-693.
[17]
Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, et al. Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines[J]. J Biol Chem, 1999, 274(48): 34343-34349.
[18]
Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin[J]. Science, 1980, 209(4458): 823-825.
[19]
Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes[J]. Diabetes Care, 2010, 33(6): 1379-1381.
[20]
Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1 alpha, 25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes[J]. FASEB J, 2002, 16(13): 1808-1810.
Mauricio D, Mandrup-Poulsen T, Nerup J. Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective[J]. Diabetes Metab Rev, 1996, 12(1): 57-68.
[23]
Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3[J]. J Steroid Biochem Mol Biol, 1995, 53(1-6): 599-602.
[24]
Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages [J]. Clin Exp Immunol, 2000, 120(1): 139-146.
[25]
Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults[J]. Diabetes Care, 2007, 30(4): 980-986.
[26]
Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene[J]. Eur J Immunol, 1998, 28(10): 3017-3030.
